000142993 001__ 142993
000142993 005__ 20240229112538.0
000142993 0247_ $$2doi$$a10.1007/s13402-018-0415-3
000142993 0247_ $$2pmid$$apmid:30456574
000142993 0247_ $$2ISSN$$a2211-3428
000142993 0247_ $$2ISSN$$a2211-3436
000142993 037__ $$aDKFZ-2019-00618
000142993 041__ $$aeng
000142993 082__ $$a610
000142993 1001_ $$0P:(DE-He78)17064a887f14c1cee3ae16af3cf73314$$aPervaiz, Asim$$b0$$eFirst author$$udkfz
000142993 245__ $$aCCR5 blockage by maraviroc: a potential therapeutic option for metastatic breast cancer.
000142993 260__ $$aHeidelberg [u.a.]$$bSpringer$$c2019
000142993 3367_ $$2DRIVER$$aarticle
000142993 3367_ $$2DataCite$$aOutput Types/Journal article
000142993 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1551855477_31081
000142993 3367_ $$2BibTeX$$aARTICLE
000142993 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000142993 3367_ $$00$$2EndNote$$aJournal Article
000142993 520__ $$aBone metastasis is observed in up to 70% of breast cancer patients. The currently available treatment options are palliative in nature. Chemokine receptor 5 (CCR5) has gained attention as therapeutic target in various malignancies. Here, we investigated the effects of targeting CCR5 by its antagonist maraviroc in metastatic breast cancer cells.In response to maraviroc exposure, cytotoxicity was assessed using an MTT proliferation assay, whereas the effects on colony formation and migration were assessed using colony formation, transwell chamber migration and scratch wound healing assays, respectively. Apoptosis-related activities were investigated using nuclear staining, annexin-V FITC staining and Western blotting. Cell cycle changes were analysed using flow cytometry and qRT-PCR for cell cycle relevant genes. A nude rat model for breast cancer bone metastasis was used to evaluate the in vivo efficacy of CCR5 targeting by maraviroc. Circulatory levels of the three cognate ligands for CCR5 (CCL3, CCL4, CCL5) were analysed in sera of breast cancer patients using ELISA.We found that blockade of CCR5 attenuated the proliferation, colony formation and migration of metastatic breast cancer cells, and induced apoptosis and arrest in the G1 phase of the cell cycle. Expression profiling highlighted the involvement of cell cycle related signalling cascades. We also found that treatment with maraviroc significantly inhibited bone metastasis in nude rats implanted with MDA-MB-231 breast cancer cells. Finally, we found that the circulatory levels of three cognate ligands for the CCR5 receptor varied between breast cancer patients and healthy controls.Our findings indicate that targeting CCR5 may be an effective strategy to combat breast cancer bone metastasis.
000142993 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000142993 588__ $$aDataset connected to CrossRef, PubMed,
000142993 7001_ $$0P:(DE-He78)8da28eac875d8c53905ac3f4393784b8$$aZepp, Michael$$b1$$udkfz
000142993 7001_ $$aMahmood, Saqib$$b2
000142993 7001_ $$0P:(DE-HGF)0$$aAli, Doaa Mohamed$$b3
000142993 7001_ $$0P:(DE-He78)7e60033e3eaaebb9ba30c905ade4a676$$aBerger, Martin$$b4$$udkfz
000142993 7001_ $$0P:(DE-HGF)0$$aAdwan, Hassan$$b5$$eLast author
000142993 773__ $$0PERI:(DE-600)2595105-1$$a10.1007/s13402-018-0415-3$$gVol. 42, no. 1, p. 93 - 106$$n1$$p93 - 106$$tCellular oncology$$v42$$x2211-3436$$y2019
000142993 909CO $$ooai:inrepo02.dkfz.de:142993$$pVDB
000142993 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)17064a887f14c1cee3ae16af3cf73314$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000142993 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8da28eac875d8c53905ac3f4393784b8$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000142993 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000142993 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)7e60033e3eaaebb9ba30c905ade4a676$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000142993 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000142993 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000142993 9141_ $$y2019
000142993 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000142993 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000142993 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000142993 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000142993 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000142993 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000142993 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000142993 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000142993 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000142993 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000142993 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000142993 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000142993 9201_ $$0I:(DE-He78)G401-20160331$$kG401$$lToxikologie und Chemotherapie$$x0
000142993 980__ $$ajournal
000142993 980__ $$aVDB
000142993 980__ $$aI:(DE-He78)G401-20160331
000142993 980__ $$aUNRESTRICTED